

CURRICULUM VITAE

Name: ILANA F. GAREEN
Associate Professor of Epidemiology (Research)

Address: Center for Statistical Sciences
Public Health Program
Alpert Medical School
Brown University
121 South Main, S-121-7
Providence, RI 02912

Phone: (401) 863-1758
Fax: (401) 863-9182
E-mail: igareen@stat.brown.edu

Education

University of California, Los Angeles, Department of Epidemiology. Ph.D. 1997.

Yale University School of Medicine, New Haven, Connecticut, Department of Epidemiology and Public Health. M.P.H. 1985.

Vassar College, Poughkeepsie, New York, Independent Major: Bioethics, A.B. 1982.

Postgraduate training

Post-doctoral Fellow, Center for Statistical Sciences, Brown University, Providence, RI, 1997-1999.

Academic appointments

Associate Professor, Department of Epidemiology, Brown University, Providence, Rhode Island. 2015-present.

Assistant Professor, Department of Epidemiology, Brown University, Providence, Rhode Island. 1999-2015.

Research Fellow, Department of Community Health, Brown University, Providence, Rhode Island. 1997-1999.

Research Fellow, Department of Diagnostic Imaging, Brown University, Providence, Rhode Island. 1997-1999.

Teaching Assistant, University of California, Los Angeles, Department of Epidemiology. 1993.

Research Associate, Department of Public Health, Cornell University Medical College, New York, New York. 1987-1989.

Other Professional Positions:

Co-Chair, ECOG-ACRIN Cancer Research Group, Patient-Reported Outcomes Working Group. 2018-present.

Co-Chair, ECOG-ACRIN Cancer Research Group, Late Effects Working Group. 2017-present.

Co-Chair, ECOG-ACRIN National Community Oncology Research Program, Cancer Care Delivery Research Committee. 2014-present.

Chair, ECOG-ACRIN Cost-Effectiveness Cross-Cutting Committee, 2014-2019.

Affiliate Member, Center for Evidence-Based Medicine, Brown University, Providence, Rhode Island. 2014-present.

Director, ECOG-ACRIN Outcome and Economics Assessment Unit. 2002-present.

Member, ACRIN Outcomes Committee, 1999-2014.

Director, ACRIN Outcome and Economics Core Laboratory. 2002-2014.

Member, Center for Statistical Sciences, Brown University, Providence, Rhode Island, 1997-present.

Awards and Honors:

American College of Radiology Imaging Network Outstanding Contribution Award 2008.

American College of Radiology Imaging Network Outstanding Contribution Award 2002.

Pew Health Policy Fellow, RAND/University of California, Los Angeles, 1989-1992.

Major Committee Assignments:

Moderator, Asia-Pacific Economic Cooperation forum (APEC) virtual workshop on Cancer Control Policy – Thematic Session 2: Screening and Early Detection, Accelerating Implementation of Cancer Control Programs in APEC Economies through Innovation and Partnership, facilitated by the APEC Life Sciences Innovation Forum on behalf of the Ministry of Health and Welfare (MoHW), Chinese Taipei.(October 2021).

Member, Health Services: Quality and Effectiveness Study Section, Center for Scientific Review, National Institutes of Health, March 2021-2022.

Member, Advisory Panel on Clinical Trials, Patient-Centered Outcome Research Institute 2020- present.

Member, Health Services Organization and Delivery Study Section, Center for Scientific Review, National Institutes of Health, July 2018-2020.

Member, NIH Special Emphasis Panel 2017/10 ZCA1 SRB-5 (O1) R: NCI Research and Coordinating Center for Population-based Research to Optimize the Screening Process Review Meeting, June 13, 2017.

Member, NIH Special Emphasis Panel ZRG1 PSE-H 50: Cancer-Related Behavioral Research through Integrating Existing Data applications. Center for Scientific Review, National Institutes of Health, September 22, 2017.

Temporary Member, Health Services Organization and Delivery Study Section, Center for Scientific Review, National Institutes of Health, February 2016, February 2017.

Member, CDC Expert Panel on Lung Cancer Screening Surveillance. April 15, 2013.

Member, Planning Committee, Symposium on Comparative Effectiveness of Advanced Imaging in Cancer, April 30, 2012.

Member, Data Safety Monitoring Board, “Protective Effects of Delayed Cord Clamping in Very Low Birth Weight Infants” 2010-2013.

Co-Chair, National Lung Screening Trial, Epidemiology Working Group, 2008-2012.

Member, National Institutes of Health, Office of the Director, Office of Medical Applications of Research (OMAR), and the National Institute of Diabetes and Digestive and Kidney Diseases, NIH Consensus Development Conference: Management of Hepatitis B. 2008.

Co-chair, the National Cancer Institute's NLST Smoking Working Group on Risk Perception. January 2003-2006.

Member, National Cancer Institute, Panel on Common Data Elements for Helical CT Screening of Lung Cancer 2000-2001.

Manuscript Reviewer

American Thoracic Society

BMC Primary Care

Cancer

Chest

Generating Evidence & Methods to improve patient outcomes

JAMA

Journal of Clinical Oncology

Journal of Nuclear Medicine

Journal of Psychosomatic Research

Medical Care

Obstetrics & Gynecology

Radiology

Statistics in Medicine

Editorial board

Member, Cancer Control, 2017-present

Academic Editor, Medicine, 2014-2017

Associate Editor, Epidemiologic Perspectives & Innovations, 2004-2012

Original publications in peer-reviewed journals

1. Staiano-Coico L, Wong R, Jacobsen I, Morrissey KP, Lesser ML, Gareen IF, McMahon C, Cennerazzo W, Decosse J. DNA content of rectal scrapings from individuals with familial adenomatous polyposis syndrome: an interim report. *Cancer* 1989;64:2579-2584.
2. Wojtasek DA, Texidor HS, Govini AF, and Gareen IF. Diagnostic quality of mammograms obtained with a new low-radiation-dose dual-screen and dual-emulsion film combination. *AJR* 1990;154:265-270.
3. Dicostanzo D, Rosen PP, Gareen I, and Lesser M. Prognosis in infiltrating lobular carcinoma: an analysis of "classical" and variant tumors. *Am J Surg Pathol* 1990;14:12-23.
4. Gareen I, Greenland S, and Morgenstern H. Intrauterine Devices and Pelvic Inflammatory Disease: Meta-analyses of Published Studies, 1974-1990 *Epidemiology* 2000;11:589-597.
5. Lonks JR, Garau J, Gomez L, Xercavins M, Ochoa De Echaguen A, Gareen IF, Reiss PT, Medeiros AA. Failure of Macrolide Antibiotic Treatment in Patients with Bacteremia Due to Erythromycin-Resistant *Streptococcus pneumoniae*. *Clin Infect Dis*. 2002;35:556-64.
6. Mainiero MB, Gareen IF, Bird CE, Smith W, Cobb C, Schepps B. Preferential use of sonographically guided biopsy to minimize patient discomfort and procedure time in a percutaneous image-guided breast biopsy program. *J Ultrasound Med* 2002;21:1221-1226.
7. Mayo-Smith WW, Rhea JT, Smith WJ, Cobb CM, Gareen IF, Dorfman GS. Transportable versus fixed platform CT scanners: comparison of costs. *Radiology*. 2003;226:63-8.

8. Gareen IF. Intrauterine devices and pelvic inflammatory disease. *Curr Womens Health Rep.* 2003;3:280-7.
9. Gareen I, Gatsonis C. A primer on multiple regression models for diagnostic imaging research, *Academic Radiology*, 2003;229:305-10.
10. Gareen I, Morgenstern H, and Greenland S. Explaining the association of maternal age with cesarean delivery for nulliparous and parous women, *J Clin Epidemiol.* 2003; 56: 1100-10.
11. Church T. and NLST Executive Committee Chest radiography as the comparison for spiral CT in the National Lung Screening Trial. *Academic Radiology*, 2003;10:713-715. PMID:12809426.
12. Lazarus E, Mainiero MB, Gareen IF. Effect of referring physician specialty and practice type on referral for image-guided breast biopsy. *Journal of the American College of Radiology*, 2005;2:488-493.
13. Gareen IF. Non-compliance in cancer screening trials, *Clinical Trials.* 2007;4(4):341-9.
14. Hillner BE, Liu D, Coleman RE, Shields AF, Gareen IF, Hanna L, Stine SH, Siegel BA. The National Oncologic PET Registry (NOPR): design and analysis plan. *J Nucl Med.* 2007 Nov;48(11):1901-8.
15. Hillner BE, Siegel BA, Liu D, Shields AF, Gareen IF, Hanna L, Stine SH, Coleman RE. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. *J Clin Oncol.* 2008 May 1;26(13):2155-61.
16. Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Sorrell MF, Strader DB, Trotter HT. NIH Consensus Development Statement on Management of Hepatitis B. *NIH Consens State Sci Statements.* 2008 Oct 22-24;25(2):1-29.
17. Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hunt E, Coleman RE. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. *J Nucl Med.* 2008 Dec;49(12):1928-35.
18. Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hanna L, Stine SH, Coleman RE. The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry. *Cancer.* 2009 Jan 15;115(2):410-8.
19. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter HT. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. *Ann Intern Med.* 2009 Jan 20;150(2):104-10.
20. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter HT. National Institutes of Health consensus development conference statement: management of hepatitis B. *Hepatology.* 2009 May;49(5 Suppl):S4-S12.
21. Park ER, Ostroff JS, Rakowski W, Gareen IF, Diefenbach MA, Feibelman S, Rigotti NA. Risk perceptions among participants undergoing lung cancer screening: baseline results from the national lung screening trial. *Ann Behav Med.* 2009 Jun;37(3):268-79.
22. National Lung Screening Trial Research Team; Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, Galen B, Gareen IF, Gatsonis C, Goldin J, Gohagan JK, Hillman B, Jaffe C, Kramer BS, Lynch D, Marcus PM, Schnall M, Sullivan DC, Sullivan D, Zylak CJ. The National Lung Screening Trial: Overview and Study Design. *Radiology.* 2010 Nov 2. *Radiology.* 2011 Jan;258(1):243-53. Epub 2010 Nov 2. PMID: 21045183.
23. National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, Clapp JD, Clingan KL, Gareen IF, Lynch DA, Marcus PM, Pinsky PF. Baseline Characteristics of Participants in the Randomized National Lung Screening Trial. *J Natl Cancer Inst.* 2010 Dec 1;102(23):1771-9. Epub 2010 Nov 22. PMID: 21119104.
24. Hillner BE, Siegel BA, Shields AF, Duan F, Gareen IF, Hanna L, Coleman RE. Impact of Dedicated Brain PET on Intended Patient Management in Participants of the National Oncologic PET Registry. *Mol*

Imaging Biol. 2011 Feb;13(1):161-5. PubMed PMID: 21080232.

25. Vanness DJ, Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Gareen IF, Herman BA, Kuntz KM, Zauber AG, van Ballegooijen M, Feuer EJ, Chen MH, Johnson CD. Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations. *Radiology*. 2011 Nov;261(2):487-98. Epub 2011 Aug 3. PubMed PMID: 21813740; PubMed Central PMCID: PMC3198218.
26. Arthur E. Stillman, MD, PhD; Pamela K. Woodard, MD; RESCUE Investigators. Consequence of Overuse of Invasive Coronary Angiography. *Arch Intern Med*. 2011;171(7):702-710. doi:10.1001/archinternmed.2011.112.
27. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med*. 2011 Aug 4;365(5):395-409. Epub 2011 Jun 29. PubMed PMID: 21714641.
28. Marcus PM, Gareen IF, Miller AB, Rosenbaum J, Keating K, Aberle DR, Berg CD. The National Lung Screening Trial's Endpoint Verification Process: determining the cause of death. *Contemp Clin Trials*. 2011 Nov;32(6):834-40. Epub 2011 Jul 18. PubMed PMID: 21782037; PubMed Central PMCID: PMC3185147.
29. Hillner BE, Siegel BA, Hanna L, Shields AF, Duan F, Gareen IF, Quinn B, Coleman RE. Impact of 18F-FDG PET Used After Initial Treatment of Cancer: Comparison of the National Oncologic PET Registry 2006 and 2009 Cohorts. *J Nucl Med*. 2012 May;53(5):831-7. Epub 2012 Mar 23. PubMed PMID: 22448033.
30. Gareen IF, Sicks J, Adams A, Moline D, Coffman-Kadish N, Aberle DR. Identifying and collecting pertinent medical records for centralized abstraction in a multi-center randomized clinical trial: The model used by the American College of Radiology arm of the National Lung Screening Trial. *Contemp Clin Trials*. 2013 Jan;34(1):36-44. doi: 10.1016/j.cct.2012.09.002. Epub 2012 Sep 11.
31. Park ER, Gareen IF, Jain A, Ostroff JS, Duan F, Sicks JD, Rakowski W, Diefenbach M, Rigotti NA. Examining whether lung screening changes risk perceptions: National Lung Screening Trial participants at 1-year follow-up. *Cancer*. 2013 Apr 1;119(7):1306-13. doi: 10.1002/cncr.27925. Epub 2012 Dec 20. PMID: 23280348
32. National Lung Screening Trial Research Team, Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gierada DS, Jones GC, Mahon I, Marcus PM, Sicks JD, Jain A, Baum S. Results of initial low-dose computed tomographic screening for lung cancer. *N Engl J Med*. 2013 May 23;368(21):1980-91. doi: 10.1056/NEJMoa1209120. PubMed PMID: 23697514; PubMed Central PMCID: PMC3762603.
33. Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gatsonis CA, Gierada DS, Jain A, Jones GC, Mahon I, Marcus PM, Rathmell JM, Sicks J; National Lung Screening Trial Research Team. Results of the two incidence screenings in the National Lung Screening Trial. *N Engl J Med*. 2013 Sep 5;369(10):920-31. doi: 10.1056/NEJMoa1208962. PubMed PMID: 24004119.
34. Park ER, Streck JM, Gareen IF, Ostroff JS, Hyland KA, Rigotti NA, Pajolek H, Nichter M. A Qualitative Study of Lung Cancer Risk Perceptions and Smoking Beliefs Among National Lung Screening Trial Participants. *Nicotine Tob Res*. 2013 Sep 2. [Epub ahead of print] PubMed PMID: 23999653.
35. Gareen IF, Duan F, Greco EM, Snyder BS, Boiselle PM, Park ER, Fryback D, Gatsonis C. Impact of lung cancer screening results on participant health-related quality of life and state anxiety in the National Lung Screening Trial. *Cancer*. 2014 Nov 1;120(21):3401-9. doi: 10.1002/cncr.28833. Epub 2014 Jul 25. PubMed PMID: 25065710; PubMed Central PMCID: PMC4205265.
36. Black WC, Gareen IF, Soneji SS, Sicks JD, Keeler EB, Aberle DR, Naeim A, Church TR, Silvestri GA,

- Gorelick J, Gatsonis C; National Lung Screening Trial Research Team. Cost-effectiveness of CT screening in the National Lung Screening Trial. *N Engl J Med*. 2014 Nov 6;371(19):1793-802. doi: 10.1056/NEJMoa1312547. PubMed PMID: 25372087.
37. Clark MA, Gorelick JJ, Sicks JD, Park ER, Graham AL, Abrams DB, Gareen IF. The Relations between False Positive and Negative Screens and Smoking Cessation and Relapse in the National Lung Cancer Screening Trial: Implications for Public Health. *Nicotine Tob Res*. 2015 Mar 6. pii: ntv037. [Epub ahead of print] PubMed PMID: 25746779.
 38. Park ER, Gareen IF, Japuntich S, Lennes I, Hyland K, DeMello S, Sicks JD, Rigotti NA. Primary Care Provider-Delivered Smoking Cessation Interventions and Smoking Cessation Among Participants in the National Lung Screening Trial. *JAMA Intern Med*. 2015 Jun 15. doi: 10.1001/jamainternmed.2015.2391. [Epub ahead of print] PubMed PMID: 26076313.
 39. Gareen IF, Siewert B, Vanness DJ, Herman B, Johnson CD, Gatsonis C. Patient willingness for repeat screening and preference for CT colonography and optical colonoscopy in ACRIN 6664: the National CT Colonography trial. *Patient Prefer Adherence*. 2015 Jul 23;9:1043-51. doi: 10.2147/PPA.S81901. PubMed PMID: 26229451; PubMed Central PMCID: PMC4516344.
 40. Kumar P, Gareen IF, Lathan C, Sicks JD, Perez G, Hyland K, Park ER. Racial differences in tobacco cessation and treatment utilization following lung screening: an examination of the National Lung Screening Trial. *Oncologist*. 2016 Jan;21(1):40-9. doi: 10.1634/theoncologist.2015-0325. Epub 2015 Dec 28.
 41. Marcus PM, Doria-Rose VP, Gareen IF, Brewer B, Clingan K, Keating K, Rosenbaum J, Rozjabek HM, Rathmell J, Miller AB. Did death certificates and a death review process agree on lung cancer cause of death in the National Lung Screening Trial? *Clin Trials*. 2016 Mar 22. pii: 1740774516638345. [Epub ahead of print] PubMed PMID: 27006427.
 42. Trosman JR, Carlos RC, Simon MA, Madden DL, Gradishar WJ, Benson AB 3rd, Rapkin BD, Weiss ES, Gareen IF, Wagner LI, Khan SA, Bunce MM, Small A, Weldon CB. Care for a Patient With Cancer As a Project: Management of Complex Task Interdependence in Cancer Care Delivery. *J Oncol Pract*. 2016 Nov;12(11):1101-1113. PubMed PMID: 27577619.
 43. Stillman AE, Gatsonis C, Lima JA, Black WC, Cormack J, Gareen I, Hoffmann U, Liu T, Mavromatis K, Schnall MD, Udelson JE, Woodard PK. Rationale and design of the Randomized Evaluation of patients with Stable angina Comparing Utilization of noninvasive Examinations (RESCUE) trial. *Am Heart J*. 2016 Sep;179:19-28. doi:10.1016/j.ahj.2016.06.003. PubMed PMID: 27595676.
 44. Gareen IF, Hillner BE, Hanna L, Makineni R, Duan F, Shields AF, Subramaniam RM, Siegel B. Hospice Admission and Survival following (18)F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry. *J Nucl Med*. 2017 Dec 28. pii: jnumed.117.205120. doi:10.2967/jnumed.117.205120. [Epub ahead of print] PubMed PMID: 29284672.
 45. Hillner BE, Hanna L, Makineni R, Duan F, Shields AF, Subramaniam RM, Gareen I, Siegel BA. Intended vs. Inferred Treatment after (18)F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry. *J Nucl Med*. 2017 Nov 30. pii: jnumed.117.205047. doi: 10.2967/jnumed.117.205047. [Epub ahead of print] PubMed PMID: 29191854.
 46. Gareen IF, Black WC, Tosteson T, Wang Q, Tosteson A. Medical costs were similar across the CT and chest X-ray arms of the National Lung Screening Trial despite different rates of significant incidental findings. 2018 May;56(5):403-409. doi:10.1097/MLR.0000000000000900. PubMed PMID: 29613874; PubMed Central PMCID:PMC6085094.
 47. Perez GK, Gareen IF, Sicks J, Lathan C, Carr A, Kumar P, Ponzani C, Hyland K, Park ER. Racial Differences in Smoking-related Disease Risk Perceptions Among Adults Completing Lung Cancer Screening: Follow-up Results from the ACRIN/NLST Ancillary Study. *J Racial Ethn Health Disparities*. 2019 Feb 8. doi:10.1007/s40615-019-00566-z. [Epub ahead of print] PubMed PMID: 30737732.

48. Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, Hendrix J, Hillner BE, Olson C, Lesman-Segev OH, Romanoff J, Siegel BA, Whitmer RA, Carrillo MC. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. *JAMA*. 2019 Apr 2;321(13):1286-1294. doi: 10.1001/jama.2019.2000. PubMed PMID: 30938796.
49. Lehman CD, Gatsonis C, Romanoff J, Khan SA, Carlos R, Solin LJ, Badve S, McCaskill-Stevens W, Corsetti RL, Rahbar H, Spell DW, Blankstein KB, Han LK, Sabol JL, Bumberly JR, Gareen I, Snyder BS, Wagner LI, Miller KD, Sparano JA, Comstock C. Association of Magnetic Resonance Imaging and a 12- Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment. *JAMA Oncol*. 2019 Jan 17. doi: 10.1001/jamaoncol.2018.6269. [Epub ahead of print] PubMed PMID: 30653209.
50. Corl KA, Prodromou M, Merchant RC, Gareen I, Marks S, Banerjee D, Amass T, Abbasi A, Delcompre C, Palmisciano A, Aliotta J, Jay G, Levy MM. The Restrictive IV Fluid Trial in Severe Sepsis and Septic Shock (RIFTS): A Randomized Pilot Study. *Crit Care Med*. 2019 Jul;47(7):951-959. doi: 0.1097/CCM.0000000000003779. PubMed PMID: 30985449; PubMed Central PMCID: PMC6579683.
51. National Lung Screening Trial Research Team. Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial. *J Thorac Oncol*. 2019 Oct;14(10):1732-1742. doi: 10.1016/j.jtho.2019.05.044. Epub 2019 Jun 28. PubMed PMID: 31260833; PubMed Central PMCID: PMC6764895.
52. Comstock CE, Gatsonis C, Newstead GM, Snyder BS, Gareen IF, Bergin JT, Rahbar H, Sung JS, Jacobs C, Harvey JA, Nicholson MH, Ward RC, Holt J, Prather A, Miller KD, Schnall MD, Kuhl CK. Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening. *JAMA*. 2020 Feb 25;323(8):746-756. doi: 10.1001/jama.2020.0572. Erratum in: *JAMA*. 2020 Mar 24;323(12):1194. PMID: 32096852; PMCID: PMC7276668.
53. Chou SS, Romanoff J, Lehman CD, Khan SA, Carlos R, Badve SS, Xiao J, Corsetti RL, Javid SH, Spell DW, Han LK, Sabol JL, Bumberly JR, Gareen IF, Snyder BS, Gatsonis C, Wagner LI, Wolff AC, Miller KD, Sparano JA, Comstock CE, Rahbar H. Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). *Radiology*. 2021 Aug 3;204743. doi: 10.1148/radiol.2021204743. Epub ahead of print. PMID: 34342501.
54. Yanez B, Gray RJ, Sparano JA, Carlos RC, Sadigh G, Garcia SF, Gareen IF, Whelan TJ, Sledge GW, Cella D, Wagner LI. Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy: A Post Hoc Analysis of a Randomized Clinical Trial. *JAMA Oncol*. 2021 Jun 17. doi:0.1001/jamaoncol.2021.1693. Online ahead of print. PMID: 34137783
55. Garcia SF, Gray RJ, Sparano JA, Tevaarwerk AJ, Carlos RC, Yanez B, Gareen IF, Whelan TJ, Sledge GW, Cella D, Wagner LI. Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. *Cancer*. 2022 Feb 1;128(3):536-546. doi: 10.1002/cncr.33939. Epub 2021 Oct 6. PMID: 34614209; PMCID: PMC8776586.
56. Fazeli S, Snyder BS, Gareen IF, Lehman CD, Khan SA, Romanoff J, Gatsonis CA, Miller KD, Sparano JA, Comstock CE, Wagner LI, Carlos RC. Patient-Reported Testing Burden of Breast Magnetic Resonance Imaging Among Women With Ductal Carcinoma In Situ: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112). *JAMA Netw Open*. 2021 Nov 1;4(11):e2129697. doi: 10.1001/jamanetworkopen.2021.29697. Erratum in: *JAMA Netw Open*. 2021 Dec 1;4(12):e2141485. PMID: 34726748; PMCID: PMC8564581.
57. Ip EH, Saldana S, Miller KD, Carlos RC, Gareen IF, Sparano JA, Graham N, Zhao F, Lee JW, O'Connell NS, Cella D, Peipert JD, Gray RJ, Wagner LI. Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of

- adverse events. *Cancer*. 2021 Dec 15;127(24):4546-4556. doi: 10.1002/cncr.33992. Epub 2021 Nov 2. PMID: 34726788; PMCID: PMC8887554.
58. Bradbury AR, Lee JW, Gaieski JB, Li S, Gareen IF, Flaherty KT, Herman BA, Domchek SM, DeMichele AM, Maxwell KN, Onitilo AA, Virani S, Park S, Fallor BA, Grant SC, Ramaekers RC, Behrens RJ, Nambudiri GS, Carlos RC, Wagner LI. A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152). *Cancer*. 2022 Apr 1;128(7):1381-1391. doi: 10.1002/cncr.34063. Epub 2021 Dec 10. PMID: 34890045; PMCID: PMC8917095.
 59. Carlos RC, Obeng-Gyasi S, Cole SW, Zebrack BJ, Pisano ED, Troester MA, Timsina L, Wagner LI, Steingrimsson JA, Gareen I, Lee CI, Adams AS, Wilkins CH. Linking Structural Racism and Discrimination and Breast Cancer Outcomes: A Social Genomics Approach. *J Clin Oncol*. 2022 Feb 2;JCO2102004. doi: 10.1200/JCO.21.02004. Epub ahead of print. PMID: 35108027.
 60. Sadigh G, Gray RJ, Sparano JA, Yanez B, Garcia SF, Timsina LR, Obeng-Gyasi S, Gareen I, Sledge GW, Whelan TJ, Cella D, Wagner LI, Carlos RC. Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor-Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation: A Post Hoc Analysis of a Randomized Clinical Trial. *JAMA Oncol*. 2022 Apr 1;8(4):579-586. doi: 10.1001/jamaoncol.2021.7656. PMID: 35175284; PMCID: PMC8855314.
 61. Obeng-Gyasi S, Graham N, Kumar S, Lee JW, Jacobus S, Weiss M, Cella D, Zhao F, Ip EH, O'Connell N, Hong F, Peipert DJ, Gareen IF, Timsina LR, Gray R, Wagner LI, Carlos RC. Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients. *Blood Cancer J*. 2022 Apr 1;12(4):53. doi: 10.1038/s41408-022-00648-y. PMID: 35365604; PMCID: PMC8975964.
 62. Fazeli S, Snyder BS, Gareen IF, Lehman CD, Khan SA, Romanoff J, Gatsonis CA, Corsetti RL, Rahbar H, Spell DW, Blankstein KB, Han LK, Sabol JL, Bumberry JR, Miller KD, Sparano JA, Comstock CE, Wagner LI, Carlos RC. Association Between Surgery Preference and Receipt in Ductal Carcinoma In Situ After Breast Magnetic Resonance Imaging: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112). *JAMA Network Open*. 2022 May 2;5(5):e2210331. doi:10.1001/jamanetworkopen.2022.10331. PMID: 35536580.
 63. Goshe BM, Rasmussen AW, Wagner LI, Sicks JD, Gareen IF, Carlos RC, Herman BA, Walter AW, Regan S, Levy DE, Mahon I, Muzikansky A, Neil JM, Lui M, Dilip D, Malloy L, Gonzalez I, Finkelstein-Fox L, McCann C, Perez E, Ostroff JS, Park ER. Study protocol for a hybrid type 1 effectiveness-implementation trial testing virtual tobacco treatment in oncology practices [Smokefree Support Study 2.0]. *BMC Public Health*. 2022 Jul 15;22(1):1359. doi: 10.1186/s12889-022-13631-w. PMID: 35841024; PMCID: PMC9284951.
 64. Ghazal LV, Cole S, Salsman JM, Wagner L, Duan F, Gareen I, Lux L, Parsons SK, Cheung C, Loeb DM, Prasad P, Dinner S, Zebrack B. Social Genomics as a Framework for Understanding Health Disparities Among Adolescent and Young Adult Cancer Survivors: A Commentary. *JCO Precis Oncol*. 2022 Jun;6:e2100462. doi: 10.1200/PO.21.00462. PMID: 35772048; PMCID: PMC9259142.
 65. Wilkins CH, Windon CC, Dilworth-Anderson P, Romanoff J, Gatsonis C, Hanna L, Apgar C, Gareen IF, Hill CV, Hillner BE, March A, Siegel BA, Whitmer RA, Carrillo MC, Rabinovici GD. Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia: A Secondary Analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Cohort Study. *JAMA Neurol*. 2022 Oct 3;79(11):1139-47. doi: 10.1001/jamaneurol.2022.3157. Epub ahead of print. PMID: 36190710; PMCID: PMC9531087.
 66. Gareen IF, Gutman R, Sicks J, Tailor TD, Hoffman RM, Trivedi AN, Flores E, Underwood E, Cochancela J, Chiles C. Significant Incidental Findings in the National Lung Screening Trial. *JAMA Intern Med*. 2023 May 8. doi: 10.1001/jamainternmed.2023.1116. Epub ahead of print. PMID: 37155190.

67. Lin MY, Liu T, Sicks JS, Shih S, Gatsonis C, Gareen IF. Utilization of Diagnostic Procedures Following Lung Cancer Screening in the National Lung Screening Trial (In press).
68. O'Connell N, Zhao FM, Lee JW, Ip E, Peipert, J, Graham, N, Smith, ML, Gareen, IF, Carlos, R, Obeng-Gyasi, S, Sparano, J, Shanafelt T, Thomas M, Cella D, Wagner L, Gray R. The Importance of Low and Moderate Grade Adverse Events on Patient Side-Effect Bother and Treatment discontinuation. (revision requested)
69. Vivek Narayan, , Tao Liu, , Yunjie Song, , Joshua Mitchell, , Joreen Sicks, Ilana F. Gareen, , Lova Sun, , Srinivas Denduluri, , Ciaran P Fisher, , Jesse Manikowski, , Mark Wojtowicz, , Joseph Vadakara, , Naomi Balzer Haas, , Kenneth B. Margulies, Bonnie Ky. Early Increases in Blood Pressure and Cardiovascular Events in Patients Treated with VEGFR Tyrosine Kinase Inhibitors (revision requested)
70. Joanna M Streck, Ju-Whei Lee, Angela Wangari Walter, Rachel Rosen, Illana Gareen, Sheetal Kircher, Benjamin Herman, Ruth Carlos, Shaji K Kumar, Ingrid A. Mayer, Nabil F. Saba, Tim Fenske, Joel W. Neal, Michael B. Atkins, F. Stephen Hodi, Christos E. Kyriakopoulos, Clare M Tempany, Tait D. Shanafelt, Lynne Wagner, Stephanie R Land, Elyse R Park, and Jamie S. Ostroff, Cigarette and alternative tobacco product use among adult cancer patients enrolled in 9 ECOG-ACRIN clinical trials (revision requested)
71. Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen IF, Gutman R, Song Y, Hanna L, Hendrix J, Hillner BE, Olson C, Lesman-Segev OH, Romanoff J, Siegel BA, Whitmer RA, Carrillo MC. Impact of Amyloid Plaque PET on Health Care Utilization Among Medicare Beneficiaries with Mild Cognitive Impairment or Dementia (draft)
72. Zhao F, Peipert JD, Lee JW, Ip EH, O'Connell N, Carlos R, Gareen IF, Sparano J, Smith ML, Cella D, Gray RJ, Wagner LI. Does pre-treatment patient-reported side effect bother predict early discontinuation? An analysis of treatment tolerability across nine ECOG-ACRIN trials (draft)

Other publications

- Morgenstern H, Gareen IF, Senterfitt JW, Greenland S. Intrauterine-device Use and Pelvic Inflammatory Disease: A Meta-analysis of Published Results, 1974-90. Report to the Dalkon Shield Claimants Trust, 1994.
- Gatsonis, C, Carlos R, Gareen I, Gorelick J, Kessler L, Lau J, Rutter C, Schmid C, Tosteson A, Trikalinos T. Standards in the Design, Conduct and Evaluation of Diagnostic Testing For Use in Patient Centered Outcomes Research. 2012. Available at <http://www.pcori.org/assets/Standards-in-the-Design-Conduct-and-Evaluation-of-Diagnostic-Testing-for-Use-in-Patient-Centered-Outcomes-Research.pdf>

Invited presentations

- Invited Moderator, Asia-Pacific Economic Cooperation (APEC) Life Sciences Innovation Forum, Cancer Control Policy – *Thematic Session 2: Screening and Early Detection*, 26 October 2021.
- Invited Panel Member, Patient Centered Imaging: Research, Dissemination and Practice, Patient Centered Research in Imaging Care Delivery, Radiologic Society of North America, Chicago, IL, November 2019.
- Invited Panel Member, Patient Centered Imaging: Research, Dissemination and Practice, Patient Centered Research in Imaging Care Delivery, Radiologic Society of North America, Chicago, IL, November 2018.
- Invited Speaker, Dana Farber/Harvard Cancer Center Cancer Care Delivery Research Seminar, “Lung screening: research into comparative costs in the low-dose CT and chest X-ray arms of the National Lung Screening Trial, the importance of significant incidental findings, and planned work to compare lung screening efficacy in the NLST versus effectiveness in community lung screening.” February 6,

2018.

Invited Panel Member, Patient Centered Imaging: Research, Dissemination and Practice, Patient Centered Research in Imaging Care Delivery, Radiologic Society of North America, Chicago, IL, November 2017.

Panel member PCORI at ECOG-ACRIN Annual Meeting, Washington, DC, May 2017.

Panel member ECOG-ACRIN/Patient Centered Outcomes Research Institute Comparative Effectiveness Research Workshop, Feb 2017

Invited Speaker, Lung Cancer Screening, Cancer Grand Rounds, Rhode Island Hospital, June 11, 2015.

Invited Speaker, Lung Cancer Screening: A Debate of Practice, Policy, and Science, Society for Medical Decision Making, October 18, 2014.

Invited Panel Member, RSNA/NIBIB Workshop on Comparative Effectiveness Research (CER) for Diagnostic Imaging II, October 18-19, 2012.

Panel Member, Lung Cancer Screening: Accomplishments and Challenges, Symposium on Comparative Effectiveness of Advanced Imaging in Cancer, April 30, 2012.

Invited Speaker, National Cancer Institute Risk Perception Branch, "Smoking Behavior Data Collected in the ACRIN arm of the National Lung Screening Trial (NLST)," October 11, 2011.

Invited Speaker, ACRIN Plenary Session, "Smoking Cessation Behavior in the National Lung Screening Trial (NLST)," September 22, 2011.

Invited Speaker, National Cancer Advisory Board, "ACRIN: Studies to Evaluate the Impact of NLST Screening on Smoking Behaviors and Participant Quality of Life," June 28, 2011.

Invited Speaker, Eastern Cooperative Oncology Group Annual Meeting, "Outcomes Data Collection in American College of Radiology Imaging Group Studies." June 10, 2011.

Invited Panel member, FDA Public Workshop "Study Methodology for Diagnostics in the Post-Market Setting, May 12, 2011.

Invited Panel Member, RSNA/NIBIB Workshop on Comparative Effectiveness Research (CER) for Diagnostic Imaging, April 22-23, 2010.

Invited participant, National Cancer Institute, Non-Invasive Autopsy Workshop, March, 2003.

Invited participant, National Cancer Institute/American Cancer Society, Lung Cancer Early Detection Workshop, March 7-8 2001, Washington, DC.

Invited Speaker, Cochrane Collaboration. Invited speaker, Society for Health Services Research in Radiology Annual Meeting, October 1, 1999. Invited Speaker,

Introduction to Epidemiologic Methods. Invited speaker, Society for Health Services Research in Radiology Annual Meeting, October 23, 1998.

Abstracts

1. Dicostanzo D, Gareen I, Lesser M and Rosen, PP. Infiltrating lobular carcinoma (IFLC): a long term follow-up study of 176 patients. Presented at the International Academy of Pathology Annual Meeting, February 26, 1988.
2. Gareen I, Morgenstern H, and Greenland S. Explaining the association between maternal age and risk of cesarean delivery. Presented at the Society For Epidemiological Research Annual Meeting, June 13, 1997.
3. Gareen I, Greenland S, and Morgenstern H. Mixed and missing data categories in meta-analyses. Presented at the Society For Epidemiological Research Annual Meeting, June 26, 1998.

4. Gareen I, Morgenstern H, and Greenland S. Adverse outcomes of repeat elective cesarean section. Presented at the Society For Epidemiological Research Annual Meeting, June 26, 1998.
5. Gareen I, Aberle D, Black WC, Goldin J, Fryback D, Gatsonis C. Study design considerations for a multi-center randomized clinical trial to evaluate helical low-dose computed-tomography for lung cancer screening, Presented at the Society For Epidemiological Research Annual Meeting, June 15, 2000.
6. Mainiero M, Gareen I, Sheps B, Bird C, Cobb C, Smith W. Comparison of stereotactically-guided and ultrasound-guided core-needle biopsy with respect to procedure time and patient satisfaction. Presented at the Society For Epidemiological Research Annual Meeting, June 16, 2000.
7. Mainiero MB, Schepps B, Gareen I, Bird CE. Comparison of stereotactic and ultrasound-guided breast biopsy with respect to procedure time and patient satisfaction, Presented at the RSNA Annual Meeting, November 2000.
8. Dupuy DE, Gareen IF, Mayo-Smith WW, Vaccaro JP, Cronan JJ. The clinical utility of tissue harmonics imaging and abdominal ultrasound, Presented at the RSNA Annual Meeting, November 2000.
9. Mayo-Smith WW, Cobb CM, Smith W, Gareen IF, Dorfman GS. Comparison of hospital personnel costs using transportable versus fixed-platform CT scanners, Presented at the RSNA Annual Meeting, November 2000.
10. Design and analysis considerations in the assessment of new diagnostic imaging technologies. Gareen I, Toledano A, Blume J, Gatsonis C. Presented at the Society For Epidemiological Research Annual Meeting, June 14, 2001.
11. Aragaki C, Fischbach LA, Field C, Culica D, Mercer Q, Hynan L, Gatchel R, Gareen I, Coyle YM. A new method for analyzing quality of life: application to severe persistent asthma. Presented at the Causal Inference Conference, August 9-11, 2001.
12. Delzell P, Gareen I, Petchprapa C, et al. Ultrasound of the Shoulder. Presented at RSNA, November 2001.
13. Aragaki C, Fischbach L, Field C, Culica D, Mercer Q, Hynan L, Gatchel R, Gareen I, Coyle Y. An internet-based tool for patient-based decision analysis: application to severe persistent asthma. Presented at the Society for Epidemiologic Research Annual Meeting, June 2002
14. Gareen I. Do we have enough information to conclude that there is no association between intrauterine device use and pelvic inflammatory disease? Presented at the Society for Epidemiologic Research Annual Meeting, June 2003.
15. Gareen I. Issues to be considered when incorporating quality of life, health status, and other outcome measures into epidemiological research. Presented at the Society for Epidemiologic Research Annual Meeting, June 2003.
16. Gareen IF, Clark M, Park E, Sicks J. Baseline smoking characteristics and intention to quit in participants enrolled in the American College of Radiology National Lung Screening Trial . Presented at the Society for Epidemiologic Research Annual Meeting, June 2004.
17. Gareen IF, Clark M, Sicks J, Fryback D. The Impact Of Smoking Status And Smoking Cessation On Health Related Quality Of Life in the American College of Radiology Imaging Network National Lung Screening Trial Presented at the Society for Epidemiologic Research Annual Meeting, June 2004.
18. Gareen IF, Potential confounding of the association between screening arm and cancer mortality in population-based screening trials by screening test-related factors. Presented at the Society for Epidemiologic Research Annual Meeting, June 2005.
19. Gareen IF, Potential Factors that may Influence Measurement of Outcomes in Clinical Trials to Evaluate Screening Modalities. Presented at the Society for Epidemiologic Research Annual Meeting, June 2005.
20. Gareen IF, The potential impact of differential non-compliance in screening trials. Presented at the Society for Epidemiologic Research Annual Meeting, June 2006.

21. Park ER, Gareen I, Rakowski W, Ostroff J, Perry K, Rigotti NA. Risk Perceptions among participants of the National Lung Cancer Screening Trial. Presented at the Society of Behavioral Medicine's 28th Annual Meeting and Scientific Sessions, March 21-24, 2007.
22. Gareen IF, Centralized data collection of participant-reported outcomes in multi-site American College of Radiology Imaging Network studies. Presented at the Society for Epidemiologic Research Annual Meeting, June 2007.
23. Gareen IF, Collecting medical record information in a multi-center study. Presented at the Society for Epidemiologic Research Annual Meeting, June 2007.
24. Siewert B, Gareen I, Vanness D, Herman B, Johnson CD, Gatsonis C. ACRIN 6664 - Patient acceptance and preference of CT colonography compared to optical colonoscopy for colon cancer screening, Presented at ASCO, May 2009.
25. Gareen IF, Hillner BE, Siegel BA, Shields AF, Duan F, Hanna L, Stine SH, RE Coleman
The National Oncologic PET Registry: a Data Source for Health Services Research, Presented at the Society for Epidemiologic Research, June 2009.
26. Streck JS, Gareen I, Nichter M, Ostroff J, Rigotti NA, Hyland K, Park ER. Exploring risk perceptions following lung screening: a qualitative study among ACRIN National Lung Screening Trial (NLST) Participants. Presented at the SRNT Annual Meeting, March 2013.
27. Gareen IF, Duan F, Snyder BS, Sick J. Patient Reported outcome form response rates for two American College of Radiology Imaging Network Centralized cancer screening trials using a centralized administration model. Presented at the Society for Epidemiologic Research Annual Meeting 2013.
28. Gareen IF, Park E, et al. The effects of physician-delivered brief smoking cessation on ACRIN/NLST participants' smoking behaviors. Presented at ACSO 2013 Annual Meeting.
29. Lathan C, Park E, Gareen I, Racial differences in perceived risk in participants enrolled in the American College of Radiology (ACRIN-6654) arm of the National Lung Screening Trial (NLST). Presented at ASCO 2013 Annual Meeting.
30. Park E, Gareen, I, Sicks, J, Hyland K, Streck J, Ostroff J, Nichter M, Rigotti N. Lung screening's effect on perceived risk: implications for tobacco treatment., presented at the Society of Behavioral Medicine, Philadelphia, Pennsylvania, April 2014.
31. Perez GK, Gareen IF, Kumar P, Lathan C, Sicks J, Hyland K, Park ER. Racial Differences In Smoking Behaviors Among Participants In The Acrin National Lung Screening Trial (NLST). Presented at the Society for Research on Nicotine and Tobacco Annual Meeting February 2015.
32. Ruth C. Carlos, Bradley S. Snyder, Constance D. Lehman, Seema A. Khan, Joseph A. Sparano, Justin Romanoff, Constantine Gatsonis, Ilana F. Gareen, Ralph L. Corsetti, Habib Rahbar, Derrick W. Spell, Kenneth B. Blankstein, Linda K. Han, Jennifer L. Sabol, John R. Bumbery, Kathy D. Miller, Christopher Comstock, Lynne I. Wagner, Decision quality and quality of life after treatment for DCIS: A trial of the ECOG-ACRIN Cancer Research Group (E4112), presented at the RSNA Annual Meeting, November, 2017.
33. Rabinovici GD, Gatsonis C, Apgar C, Gareen IF, Hanna L, Hendrix J, Hillner BE, Olson C, Romanoff J, Siegel BA, Whitmer RA, Carrillo MC, and the IDEAS Study investigators, Impact Of Amyloid Pet On Patient Management: Early Results From The Ideas Study, presented at the AAIC Meeting, London, July 2017.
34. Wagner LI, Gray RJ, Garcia S, Whelan TJ, Tevarweerk A, Yanez B, Carlos R, Gareen I, McCaskill-Stevens W, Cella D, Sparano JA, Sledge, Jr. GW, On behalf of the TAILORx Study Team. Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4

Suppl):Abstract nr GS6-03.

35. Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen IF, Hanna L, Hendrix J, Hillner BE, Olson C, Lesman-Segev O, Romanoff J, Siegel BA, Whitmer RA, Carrillo MC. Amyloid PET Leads to Frequent Changes in Management of Cognitively Impaired Patients: the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study (Plen01.001) Neurology Apr 2019, 92 (15 Supplement) Plen01.001;
36. Betina Yanez, Robert J. Gray, Joseph A. Sparano, Ruth C. Carlos, Gelareh Sadigh, Sofia A. Garcia, Ilana F. Gareen, Timothy P. Whelan, George W. Sledge, David Cella, Lynne I. Wagner. Early Discontinuation to Adjuvant Endocrine Therapy in the TAILORx Trial (presented at ASCO 2020).
37. Angela R Bradbury, Ju-Whei Lee, Jill B. Gaieski, Shuli Li, Ilana F. Gareen, Keith T. Flaherty, Benjamin A. Herman, Susan M. Domchek, Angie M. DeMichele, Kara N. Maxwell, Adedayo A. Onitilo, Shamsuddin Virani, SuJung Park, Bryan A. Faller, Stefan C. Grant, Ryan C. Ramaekers, Robert J. Behrens, Gopakumar S. Hambudiri, Ruth C. Carlos, Lynne I. Wagner . Randomized trial of web-based genetic education versus usual care in advanced cancer patients undergoing tumor genetic testing: Results from the ECOG-ACRIN NCI Community Oncology Research Program (NCORP; EAQ152) COMET trial (presented at ASCO 2020).
38. Zhao F, Peipert JD, Lee JW, Hong F, Ip E, Gareen I, O'Connell NS, Carlos R, Mayer I, Miller K, Partridge A, Shanafelt T, Stewart K, Tarhini A, Thomas M, Weiss M, Sparano J, Cella D, Gray R, Wagner LI. Predictive value of bother by side effects of treatment prior to protocol therapy for early treatment discontinuation in clinical trials (presented at ASCO 2020).
39. Peipert JD, Zhao F, Lee JW, Hong F, Ip E, Gareen I, O'Connell NS, Carlos R, Stewart K, Weiss M, Sparano J, Cella D, Gray R, Wagner LI. Increase in Side Effect Bother was Associated with Early Treatment Discontinuation in a Clinical Trial among Multiple Myeloma Patients (presented at ASCO 2020).
40. Pisano E, Gatsonis C, Schnall M, Yaffe M, Troester M, Gareen I, Collins L, Curtis A, Cole E, Carlos R, Miller K, Comstock C. ECOG-ACRIN Tomosynthesis Mammographic Imaging Screening Trial (EA1151) (presented at ASCO 2020).
41. Pisano, E; Gatsonis, C; Schnall, MD; Yaffe, M; Troester, MA; Gareen, IF; Collins, LC; Curtis, A; Cole, E; Cormack, J; Carlos, R; Miller, K; Comstock, C. Engaging the radiology community in the National Clinical Trials Network: The ECOG-ACRIN TMIST experience (presented at ASCO 2021).
42. Obeng-Gyasi, S; Graham, N; Kumar, S; Lee, JW; Cella, D; Zhao, FM; Ip, E; O'Connell, N; Hong, FX; Peipert, J; Gareen, IF; Gray, RJ; Wagner, LI; Carlos, R. Association between allostatic load, symptom burden and mortality in E1A11 trial for myeloma. (presented at ASCO 2021).
43. Kircher, SM; Duan, FH; Gareen, IF; Underwood, E; Sicks, J; Suga, JMM; Kehn, H; Mehan, PT; Acoba, JD; Taylor, MA; Wagner, LI; Carlos, R. Baseline and short-term financial burden (FB) in colorectal cancer (CRC) treated with curative intent: Early results of ECOG-ACRIN EAQ162CD. (presented at ASCO 2021).
44. Fazeli, S; Snyder, B; Gareen, IF; Lehman, CD; Khan, SA; Romanoff, J; Gatsonis, C; Corsetti, RL; Rahbar, H; Spell, DW; Blankstein, KB; Han, LK; Sabol, JL; Bumberry, JR; Miller, K; Sparano, JA; Comstock, C; Wagner, LI; Carlos, R. Predictors of surgery preference and quality of life in DCIS after breast MRI: A trial of the ECOG-ACRIN Cancer Research Group (E4112). (presented at ASCO 2021)
45. Peipert, J; Zhao, FM; Lee, JW; Hong, F; Shen, SE; Ip, E; O'Connell, N; Graham, N; Smith, ML; Gareen, I; Carlos, R; Obeng-Gyasi, S; Kumar, SK; Miller, K; Partridge, A; Shanafelt, T; Sparano, JA; Stewart, K; Tarhini, A; Thomas, M; Weiss, M; Cella, D; Gray, R; Wagner, LI. Change in a single-item indicator of treatment tolerability in cancer is associated with early treatment discontinuation (presented at Quality of Life Research 2021).

46. O'Connell, N; Zhao, FM; Lee, JW; Hong, FG; Shen, SE; Ip, E; Salem, W; Peipert, J; Graham, N; Smith, ML; Gareen, I; Carlos, R; Obeng-Gyasi, S; Miller, K; Partridge, A; Shanafelt, T; Sparano, J; Stewart, K; Tarhini, A; Thomas, M; Weiss, M; Cella, D; Wagner, L; Gray, R. Low and moderate grade adverse events are important contributors to patient-reported treatment side-effect bother. (presented at Quality of Life Research 2021).
47. Zhao F, Peipert JD, Stearns V., Chang VT, Jegede O, Ip EH, Lee JW, O'Connell NS, Graham N, Henry NL, Loprinzi CL, Flynn PJ., Fisch MJ, Gareen I, Carlos RC, Smith ML, Cella D, Sparano JA, Gray RJ, Wagner LI. (Presented at ASCO 2022).
48. Pisano E, Gatsonis C, Schnall M, Yaffe M, Troester M, Gareen I, Collins L, Curtis A, Cole E, Cormack J, Steingrimsson J, Carlos R, Miller K, Comstock C. Adjusting the TMIST Study Design to Accommodate Slower than Expected Accrual: ECOG-ACRIN EA1151(Presented at ASCO 2022).
49. Kircher SM, Duan F, Underwood E, Gareen IF, Sicks J, Sadigh G, Suga JM, Kehn H, Mehan PT, Bajaj R, Hanson DA, Dalia S, Acoba DJ, Taylor MA, Wagner L, Carlos RC. Longitudinal changes in financial burden in patients with colorectal cancer treated with curative intent: Primary results of EAQ162CD (Presented at ASCO 2022).
50. Walter AW, Lee JW, Gareen IF, Kircher SM, Herman BA, Streck JM, Kumar SK, Mayer I, Saba NF, Fenske TS, Neal JW, Atkins MB, Hodi FS, EA6141 Kyriakopoulos C, Tempany-Afdhal CM, Shanafelt TD, Wagner LI, Land S, Ostroff JS, Park ER. Neighborhood socioeconomic gradients, tobacco use and cessation indicators among adults with cancer in the U.S. (Presented at ASCO 2022).
51. Narayan V, Liu T, Song Y, et al. Hypertension, cardiovascular events and survival in renal cell carcinoma and thyroid cancer patients treated with vegfr tyrosine kinase inhibitors. (Presented at JACC March 6, 2023).
52. Kuhl CK, Gatsonis CG, Newstead G, Snyder BS, An N, Gareen IF, Bergin JT, Rahbar H, Sung JS, Jacobs J, Harvey JA, Nicholson MH, Ward RC, Holt J, Prather A, Miller K, Schnall MD, Comstock CE. Incidence Round Screening Performance among Women with Dense Breasts Undergoing Abbreviated Breast MRI and Digital Breast Tomosynthesis (ECOG-ACRIN EA1141) (submitted to ASCO).
53. Park ER, Ostroff JS, Sicks JD, Goshe BM, Gareen IF, Herman BA, Taurone A, Walter AW, Regan S, Rasmussen AW, Levy DE, Muzikansky A, Thompson MA, Lui M, Malloy L, Gonzalez I, Finkelstein-Fox L., Carlos RC, Wagner LI. Smoking Cessation support and knowledge among newly diagnosed individuals at community cancer centers (ECOG-ACRIN trial EAQ171CD)(submitted to ASCO).

D. Research Support

Current Grants

1. Ilana F Gareen, PI, National Cancer Institute, Outcomes Associated with Significant Incidental Findings in Lung Cancer Screening (R01 CA204222), 03/17/2017 – 02/28/2023 (NCE), \$1,254,419
2. Ilana F. Gareen, PI, National Cancer Institute, Lung Screening: Efficacy versus Effectiveness (R01 CA215240), 01/17/2018 – 12/31/2023, \$3,038,662
3. Elyse Park, PI, Ilana F. Gareen, Co-PI, National Cancer Institute, Implementing a Virtual Tobacco Treatment in Community Oncology Practices (R01 CA214427), 02/01/2018 – 07/31/2023, \$247,172
4. Robert Gray, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN Network Group Statistics and Data Management Center (Statistical Core subaward #1800006) (U10 CA180794), 04/29/2014 – 02/28/2025, \$9,254,000
5. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN Tomosynthesis Mammographic Imaging Screen Trial (TMIST) (UG1 CA189828-06-BRWN3), 08/01/2017 – 07/31/2025, \$10,290,710

6. Robert Gray, PI, Ilana F. Gareen, Co-I, National Cancer Institute, Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability in ECOG-ACRIN Studies (U01 CA233169), 09/01/2018 – 08/31/2023, \$191,656
7. Bonnie Ky, PI, Ilana F. Green, Co-I, National Heart, Lung, and Blood Institute, Planning Grant for CARISMA – Cancer Therapy Risk-reduction with Intensive Systolic BP Management (R34 HL146927), 08/01/2019 – 07/31/2022, \$283,385
8. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base – CT (PRO) (UG1 CA189828-06-BRWN-EA2185-PCyst), 10/01/2019 – 07/31/2027, \$1,500,000
9. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base – CT (CEA) (UG1 CA189828-06-BRWN-EA2185-CEA), 10/01/2019 – 07/31/2027, \$1,500,000
10. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base – CCDR (UG1 CA189828-06-BRWN2), 08/01/2014 – 07/31/2025, \$1,410,414
11. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base – CT (UG1 CA189828-06-BRWN1), 08/01/2014 – 07/31/2025, \$1,414,745
12. Constantine Gatsonis, PI, Ilana F. Gareen, Co-I, ACR, Imaging Dementia - Evidence for Amyloid Scanning Study: A Study to Improve Precision in Amyloid PET Coverage and Patient Care, 07/01/2020 – 12/31/2024, \$1,770,341
13. John Salsman, PI, Ilana F. Gareen, Co-I, National Cancer Institute, Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN NCORP Trial (UG1CA189828), 08/01/2020 – 07/31/2022, \$347,246
14. Bradley Zebrack, PI, Ilana F. Gareen, Co-I, National Cancer Institute, Social Genomic Mechanisms of Health Disparities among Adolescent and Young Adult (AYA) Cancer Survivors (1R01 CA261752), 09/01/2021 – 08/31/2026, \$1,110,813
15. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base – COVID19 Supplement (5UG1CA189828-07S3), 08/01/2020 – 07/31/2022, \$88,727
16. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, Developing an Analytic Resource for Efficiently Linking EA Participants to Medicare data to identify patients with Alzheimer's disease and its related dementias (DAREtoLEAP) (3UG1 CA189828-08S1), 08/01/2021 – 07/31/2022, \$296,089
17. Galareh Sadigh, PI, Ilana F. Gareen, Co-I, National Cancer Institute, Improving medication adherence using a CONnected CUsomized Treatment Platform (CONCURxP) (1R01 CA262312-01A1), 08/01/22 – 07/31/27, \$955,099
18. Galareh Sadigh, PI, Ilana F. Gareen, Co-I, National Cancer Institute, Effectiveness of Out-of-Pocket Cost COMMunication and Financial Navigation (CostCOM) in Cancer patients (R01), 12/01/22 – 11/30/27, \$1,110,813

Grants Under Review

1. Elsy Park, PI, Ilana F. Gareen, Co-I, National Institutes of Health, A Pilot Health Insurance Navigation Intervention for Colorectal Cancer Survivors
2. Daeho Kim, PI, Ilana F. Gareen, Co-I, American Cancer Society, Effects of Medicare Advantage on Evidence-Based Screening and Early Detection of Cancer
3. Lynne Wagner, PI, Ilana F. Gareen, Co-I, National Cancer Institute, Randomized controlled trial of FoRtitude: Targeted eHealth intervention to reduce fear of recurrence among breast cancer survivors in community oncology settings
4. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Institutes of Health, Liver Imaging For Early cancer

detection (LIFE)

5. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base Grant - EA1202 DUET DCIS Study – Supplement
6. Domonique Michaud, PI, Ilana F. Gareen, Co-I, National Institutes of Health, Using DNA methylation array data to improve risk stratification and identification of lung cancers in the National Lung Screening Trial
7. Gutman/Panagiotou (MPIs), Ilana F. Gareen, Co-I, National Institutes of Health, Novel data linking approaches to estimate the risk of Alzheimer's disease and its related dementias due to cancer treatments

Completed Grants

1. Constantine Gatsonis, PI, Ilana F. Gareen, Co-I, American College of Radiology, Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Study, 06/01/15 – 12/31/20, \$3,217,134
2. Vincent Mor, PI, Ilana F. Gareen, Co-I, National Institute of Aging, Caregivers' Reactions and Experience: Imaging Dementia Evidence for Amyloid Scanning, 09/15/17 – 05/31/21, \$690,943
3. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base – CT (PCyst), 10/01/2019 – 07/31/2027, \$3,299,994
4. Apgar, Ilana F. Gareen, Co-I, ACR Foundation, EA1141 Abbreviated MRI Study, 09/16/21 – 08/31/21, \$53,021
5. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base – EASEE PRO, 08/01/18 – 07/31/19, \$19,947
6. Ilana F. Gareen, PI, NCI-NHGRI, NCI-NHGRI Precision Medicine Ancillary Studies – COMET, 03/01/17 – 02/28/18, \$79,413
7. Vincent Mor, PI, Ilana F. Gareen, Co-I, National Institute of Aging, Caregivers' Reactions and Experience: Imaging Dementia Evidence for Amyloid Scanning CARE IDEAS, 08/01/16 – 7/31/17, \$1,373,989
8. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base – Incorporating the C-TUQ among NCTN and NCORP Clinical Trial Participants, 08/01/16 – 07/31/17, \$80,694
9. Fenghai Duan, PI, Ilana F. Gareen, Co-I, Blue Earth Diagnostics, Blue Earth Diagnostics Multi-Center Trial of FACBC, 08/01/16 – 07/31/19, \$61,097
10. Fenghai Duan/Ilana F. Gareen (MPIs), World Molecular Imaging Society, NOPR NaF CMS Collaboration, 01/01/17 – 12/31/17, \$136,698
11. Mitchell Schnall, PI, Ilana F. Gareen, Co-I, Agency for Healthcare Research and Quality, ACRIN NLST Follow-Up, 03/01/16 – 02/28/17, \$15,000
12. Ilana F. Gareen PI, American College of Radiology, ACRIN Protocol 7151 Statistical Support, 04/01/11 – 12/31/15, total awarded \$268,000.
13. Constantine Gatsonis/ Mitchell Schnall MPI, Ilana F. Gareen Co-I, National Cancer Institute, NCI/ECOG-ACRIN NCORP Research Base-CT (1UG1CA189828-01-BRWN1) 08/01/14 – 07/31/16, total awarded \$410,072.
14. Constantine Gatsonis/ Mitchell Schnall (MPIs) , Ilana F. Gareen Co-I, NCI/ECOG-ACRIN NCORP Research Base - CCDD, National Cancer Institute (1UG1CA189828-01-BRWN2), 08/01/14 – 07/31/16, total awarded \$312,044.
15. Constantine Gatsonis PI, Ilana F. Gareen Co-I, ACR Foundation, RESCUE: Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Noninvasive Examinations, 09/30/13-09/29/15, total

awarded \$317,926.

16. Constantine Gatsonis/ Ilana F. Gareen (MPIs), National Cancer Institute, Biostatistics Data Management Center for ACRIN National Lung Screening Trial Supplement (U10 CA79778), 07/01/02 - 12/31/14, total awarded \$23,442,291.
17. Constantine Gatsonis PI, Ilana F. Gareen Co-I National Cancer Institute, Biostatistics Data Management Center for ACRIN (U10 CA79778), 03/01/99-12/31/14, total awarded \$17,951,912.
18. Constantine Gatsonis PI, Ilana F. Gareen Co-I, Agency for Healthcare Research, RESCUE: Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Noninvasive Examinations, 09/30/10-09/29/13, total awarded \$2,071,559.
19. Anna Tosteson PI, Constantine Gatsonis/Ilana F. Gareen Co-Sub PI, National Cancer Institute, Grand Opportunity Grant: Comparative Effectiveness of Advanced Imaging in Cancer, National Cancer Institute, RC2 CA148259, Subcontract to Dartmouth University, 09/30/09-05/31/13, total awarded \$2,071,559.
20. Constantine Gatsonis PI, Ilana F. Gareen Co-I Investigator, Academy of Molecular Imaging, National Oncologic PET Registry (NOPR), [PI: Gatsonis], 05/01/06-12/31/13, total awarded \$1,207,017.
21. Constantine Gatsonis PI , Ilana F. Gareen Co-I, Patient Centered Outcomes Research Institute, Standards in the Design, Conduct, and Evaluation of Research Evaluating Diagnostic Testing Strategies for Patient Centered Outcomes, 01/04/12-06/15/12, total awarded \$77,868.
22. Ilana F. Gareen PI, National Cancer Institute, Compliance with Lung Cancer Screening, National Cancer Institute (R03 CA 139584), 06/01/09-05/31/12, total awarded \$149,895.
23. Constantine Gatsonis, Ilana F. Gareen Co-I, National Cancer Institute, Biostatistics Data Management Center for Computerized Tomographic Colonography Trial (CTC) (5U01 CA 079778-09), 01/01/05-12/31/09, total awarded \$1,244,061.
24. Constantine Gatsonis, Ilana F. Gareen Co-I National Cancer Institute/American College of Radiology Subcontract Co-Investigator, ACRIN Fellowship (CA94032), 01/01/03-08/31/05, total awarded \$160,552.

Mentor/PhD/MPH Advisor

2022-present: MPH Thesis Advisor, Kevin Xi. M.P.H. Candidate

2022-present: MPH Thesis Advisor, Yuchen Bo, M.P.H. Candidate

2021-present: Research Mentor, Men-Yun Lin, Post-Doctoral Fellow, Wake Forest University, Supervising Manuscripts based on NLST

2020: MPH Thesis Advisor, Nishtha Baranwal, M.P.H. Candidate

2018-2023: Doctoral Committee Member, Jerson Cochancela, PhD. Candidate

2018-2022: Doctoral Committee Chair, Nana Boame, PhD. Candidate

2017-2018: Research Mentor, Stephannie Shih, Ph.D. Candidate

2015-2017: Member, Dissertation Committee Valerie Strezsak, Ph.D. Candidate

2005-2010: Elyse Park, Mentored Research Scholar Grant - American Cancer Society, “The Effect of Lung Cancer Screening on Risk Perceptions, Aim: To assess how the risk perceptions of current and former smokers are affected by the results of lung cancer screening, and to improve our understanding of the meaning of risk perceptions.” 01/01/05- 12/31/10.

2002-2004: Member, Dissertation Committee Mei-Hsui Chen, Ph.D. Candidate

2001- 2004: ACRIN Fellows, provided mentoring on Fellows’ projects. Delivered didactic sessions.

University committee roles

2022-Center for Evidence Based Medicine Faculty Search
2020-present: Member, Epidemiology Curriculum Committee
2017-present: Member, Center for Statistical Sciences Executive Committee
2016-2019: Member, Epidemiology Ph.D. Admission Committee
2015-2016 Member, Epidemiology Curriculum Committee
2015-2019: Member, Ad Hoc Committee on Research Faculty
2014-2017: Member Recruitment Committee: K12: Develop Patient Centered Outcomes Scholars for Comparative Effectiveness Research
2004-2013: Member, Epidemiology Curriculum Committee
July 2003-September 2004: Member, Faculty Search Committee, Center for Clinical Trials

University teaching roles

Fall 2020: PHP2030—Clinical Trials, 16 students enrolled
Fall 2019: PHP2030—Clinical Trials, 11 students enrolled
Fall 2018: PHP2030---Clinical Trials, 18 students enrolled
Fall 2017: PHP2030---Clinical Trials, 15 students enrolled
Fall 2016: PHP2030---Clinical Trials, 18 students enrolled
Fall 2015: PHP2030—Clinical Trials, 10 students enrolled
Fall 2014: PHP2030—Clinical Trials, 14 students enrolled
Fall 2013: PHP2030—Clinical Trials, 10 students enrolled
Fall 2012: PHP2030—Clinical Trials, 10 students enrolled
Fall 2011: PHP 1970 S16: Independent Study: Meta-Analysis, Nicole Cameron
Fall 2011: PHP2030—Clinical Trials, 19 students enrolled
Fall 2010: PHP2030—Clinical Trials, 13 students enrolled
Fall 2009: PHP2030—Clinical Trials, 32 students enrolled
Spring 2002-2007: Community Health Fellows Didactic Sessions
Fall 2005: BC0234—Clinical Trials, 16 students enrolled.
Spring 2004: BC0034—Health and Human Reproduction, 28 students enrolled
Spring 2003: BC0034—Health and Human Reproduction, 24 students enrolled
Spring 2002: Supervised Independent Study for Justine Woodfield
Spring 2002: BC0034—Health and Human Reproduction, 21 students enrolled.
Spring 2001: BC0034—Health and Human Reproduction, 46 students enrolled
Spring 2000: BC0220-Advanced Epidemiologic Methods, 6 students (including 2 auditors).